LGLisa Göschl

Lisa Göschl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa Göschl has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Bonelli

    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria

    4 shared publications
  • Daniel Aletaha

    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    3 shared publications
  • Clemens Scheinecker

    Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien (MUW), AKH Wien, Wien, Österreich

    2 shared publications
  • Daniela Sieghart

    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Elisabeth Simader

    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Günter Steiner

    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    2 shared publications

Latest Publications

  • Open Access

    ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype

    by Philipp Peters, Johanna Schepp, Michael H. Albert, Horst von Bernuth, Norbert Blank, Jürgen Brunner, Gregor Dückers, Lisa Ehlers, Susan Farmand, Dirk Föll, et al.

    Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease with diverse phenotypes. We describe the genetics, phenotypes, and treatment of n = 48 DADA2 patients from Germany, Austria, and Switzerland. We report a high incidence of hematological (83%) and immunological features (85%), a comparatively low anti-tumor necrosis factor full-response rate (58%), and a high decision probability (21%) for hematopoietic cell transplantation (HCT). We establish a correlation between genetic variant ADA2 activity and patient ADA2 activity. Remarkably, lower patient ADA2 activity is predictive of neutropenia and shows a trend toward HCT decision, whereas higher patient ADA2 activity is predictive of vasculitis symptoms. Genetic variants with low residual ADA2 activity are significantly more common among patients receiving HCT. Our study corroborates previous observations connecting ADA2 activity and clinical phenotype, which up to now have been mainly based on in vitro data.

  • Open Access

    Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy

    by Teresa Preglej, Anela Tosevska, Marie Brinkmann, Philipp Schatzlmaier, Franziska Schmidt, Jakov Korzhenevich, Elisabeth Simader, Daniela Sieghart, Philipp Hofer, Thomas Krausgruber, et al.


  • Open Access

    Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency

    by Matthias G. Vossen, Felix Kartnig, Daniel Mrak, Elisabeth Simader, Karin Stiasny, Renate Kain, Thomas Perkmann, Helmuth Haslacher, Judith H. Aberle, Leonhard X. Heinz, et al.

    Summary: Impaired immune response to COVID-19 (coronavirus disease 2019) vaccination has been reported in patients with inborn errors of immunity (IEI). Repetitive vaccinations are recommended for this vulnerable group. Due to the high diversity within IEI patients, additional safety and immunogenicity data are needed to better understand these aspects especially in less common immunodeficiency syndromes. In this prospective open-label clinical trial, we assessed the humoral immune response and the T‑cell response in patients with IEI or severe MBL (mannose-binding lectin) deficiency (IEI/MBLdef) after three vaccinations. A total of 16 patients and 16 matched healthy controls (HC) with suboptimal humoral response defined by anti-SARS-CoV‑2 RBD (severe acute respiratory syndrome coronavirus type 2 receptor binding domain) antibodies below 1500 BAU/ml (binding antibody units per ml) after the second COVID-19 vaccination were enrolled in this study and qualified for a third mRNA vaccine dose. After 4 weeks following vaccination, 100% of HC and 75% of IEI/MBLdef patients exhibited anti-SARS-CoV‑2 RBD antibodies > 1500 BAU/ml, although the difference was not statistically significant (75% vs. 100%; p = 0.109). Although post-vaccination IEI/MBLdef patients demonstrated significantly increased anti-SARS-CoV‑2 RBD antibodies and neutralizing antibodies compared to baseline, these responses were significantly lower in IEI/MBLdef patients compared to HCs. Notably, the third vaccination augmented the cellular immune response to both wild-type and omicron peptide stimulation. No serious adverse events were reported within the 4‑week follow-up period and, importantly, vaccination had little to no effect on the long-term disease activity and fatigue. This trial strongly supports the recommendation of repeated COVID-19 vaccinations for patients suffering from immunodeficiencies, especially when they exhibit an initially limited response to the vaccine.


  • Open Access

    Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach

    by Teresa Preglej, Marie Brinkmann, Günter Steiner, Daniel Aletaha, Lisa Göschl, Michael Bonelli

    Various autoimmune diseases are characterized by distinct cell subset distributions and activation profiles of peripheral blood mononuclear cells (PBMCs). PBMCs can therefore serve as an ideal biomarker material, which is easily accessible and allows for screening of multiple cell types. A detailed understanding of the immune landscape is critical for the diagnosis of patients with autoimmune diseases, as well as for a personalized treatment approach. In our study, we investigate the potential of multi-parameter spectral flow cytometry for the identification of patients suffering from autoimmune diseases and its power as an evaluation tool for in vitro drug screening approaches (advanced immunophenotyping). We designed a combination of two 22-color immunophenotyping panels for profiling cell subset distribution and cell activation. Downstream bioinformatics analyses included percentages of individual cell populations and median fluorescent intensity of defined markers which were then visualized as heatmaps and in dimensionality reduction approaches. In vitro testing of epigenetic immunomodulatory drugs revealed an altered activation status upon treatment, which supports the use of spectral flow cytometry as a high-throughput drug screening tool. Advanced immunophenotyping might support the exploration of novel therapeutic drugs and contribute to future personalized treatment approaches in autoimmune diseases and beyond.


  • Open Access

    Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation

    by Teresa Preglej, Patricia Hamminger, Maik Luu, Tanja Bulat, Liisa Andersen, Lisa Göschl, Valentina Stolz, Ramona Rica, Lisa Sandner, Darina Waltenberger, et al.

    Some effector CD4 + T cell subsets display cytotoxic activity, thus breaking the functional dichotomy of CD4 + helper and CD8 + cytotoxic T lymphocytes. However, molecular mechanisms regulating CD4 + cytotoxic T lymphocyte (CD4 + CTL) differentiation are poorly understood. Here we show that levels of histone deacetylases 1 and 2 (HDAC1-HDAC2) are key determinants of CD4 + CTL differentiation. Deletions of both Hdac1 and 1 Hdac2 alleles (HDAC1 cKO -HDAC2 HET ) in CD4 + T cells induced a T helper cytotoxic program that was controlled by IFN-γ–JAK1/2–STAT1 signaling. In vitro, activated HDAC1 cKO -HDAC2 HET CD4 + T cells acquired cytolytic activity and displayed enrichment of gene signatures characteristic of effector CD8 + T cells and human CD4 + CTLs. In vivo, murine cytomegalovirus–infected HDAC1 cKO -HDAC2 HET mice displayed a stronger induction of CD4 + CTL features compared with infected WT mice. Finally, murine and human CD4 + T cells treated with short-chain fatty acids, which are commensal-produced metabolites acting as HDAC inhibitors, upregulated CTL genes. Our data demonstrate that HDAC1-HDAC2 restrain CD4 + CTL differentiation. Thus, HDAC1-HDAC2 might be targets for the therapeutic induction of CD4 + CTLs.


  • Open Access

    CD4+CD25-Foxp3+ T cells: a marker for lupus nephritis?

    by Michael Bonelli, Lisa Göschl, Stephan Blüml, Thomas Karonitsch, Carl-Walter Steiner, Günter Steiner, Josef S Smolen, Clemens Scheinecker

    Introduction: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease, which can affect different organs. Increased proportions of CD4+CD25-Foxp3+ T cells have been described in SLE patients. The exact role of this cell population in SLE patients still remains unclear. We therefore analyzed this T cell subset in a large cohort of SLE patients with different organ manifestations. Methods: Phenotypic analyses, proportions and absolute cell numbers of CD4+CD25-Foxp3+ T cells were determined by flow cytometry (FACS) in healthy controls (HC) (n = 36) and SLE patients (n = 61) with different organ manifestations. CD4+CD25-Foxp3+ T cells were correlated with clinical data, the immunosuppressive therapy and different disease activity indices. In patients with active glomerulonephritis, CD4+CD25-Foxp3+ T cells were analyzed in urine sediment samples. Time course analyses of CD4+CD25-Foxp3+ T cells were performed in patients with active disease activity before and after treatment with cyclophosphamide and prednisone. Results: CD4+CD25-Foxp3+ T cells were significantly increased in active SLE patients and the majority expressed Helios. Detailed analysis of this patient cohort revealed increased proportions of CD4+CD25-Foxp3+ T cells in SLE patients with renal involvement. CD4+CD25-Foxp3+ T cells were also detected in urine sediment samples of patients with active glomerulonephritis and correlated with the extent of proteinuria. Conclusion: CD4+CD25-Foxp3+ T cells resemble regulatory rather than activated T cells. Comparative analysis of CD4+CD25-Foxp3+ T cells in SLE patients revealed a significant association of this newly described cell population with active nephritis. Therefore CD4+CD25-Foxp3+ T cells might serve as an important tool to recognize and monitor SLE patients with renal involvement.